← Human Trials & Peer-Reviewed Studies
Growth hormone treatment does not affect incidences of middle ear disease or hearing loss in infants and toddlers with Turner syndrome.
Plain-language guide to PMID 20424424 (2010): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 20424424
- Journal
- Hormone research in paediatrics
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Davenport ML et al. (8 authors)
- DOI
- 10.1159/000313964
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.
No randomized, controlled, prospective study has evaluated the effect of growth hormone (GH) on the rates of middle ear (ME) disease and hearing loss in girls with Turner syndrome (TS).
Who Took Part
By PubMed's age tags, the people studied were infants and young children, women only.
Eighty-eight girls with TS, aged 9 months to 4 years, were enrolled.
How the Study Was Run
The design is described as randomized, open-label and multicenter.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.
More than one site took part, so the participants came from several places.
A 2-year, prospective, randomized, controlled, open-label, multicenter, clinical trial ('Toddler Turner Study'; August 1999 to August 2003) was carried out.
The study was conducted at 11 US pediatric endocrine centers.
What Was Measured
No randomized, controlled, prospective study has evaluated the effect of growth hormone (GH) on the rates of middle ear (ME) disease and hearing loss in girls with Turner syndrome (TS).
PubMed files the paper under topics including Audiology, Cohort Studies, Hearing Loss, Human Growth Hormone, Insulin-Like Growth Factor I, Longitudinal Studies and Otitis Media.
What This Means in Plain Language
The paper is a randomized, open-label and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (Hormone research in paediatrics), a journal based in Switzerland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.